Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new probe spot hidden cancer cells?

NCT ID NCT07331532

Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive probe called 68Ga-PFA2 for PET scans. It targets a protein called annexin A2, which is found at high levels in many cancers and helps them spread. Researchers want to see if this probe can find metastases in lung cancer patients better than current standard scans. Ten adults with confirmed lung cancer will be enrolled to compare the new probe's accuracy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
68Ga-PFA2 (a radioactive imaging probe)
What this could lead to
If successful, this could provide a more accurate, non-invasive way to detect cancer spread, helping doctors tailor treatments earlier.
What could go wrong
This is a very small, early-phase study with only 10 participants, so results may not apply broadly. The probe's effectiveness compared to standard scans is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include lung cancer patients, both suspected and confirmed, who are scheduled to undergo PET/CT imaging using the 68Ga-PFA2 probe. The study will focus on patients aged 18-80 years with confirmed lung cancer, and the participants should be able to understand the study protocol, provide informed consent, and cooperate with examination procedures.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18-80 years. * Diagnosed with confirmed lung cancer. * Scheduled to undergo pathological tissue biopsy or surgical treatment within the next two months. * Able to fully comprehend and voluntarily participate in the study. * Able to provide informed consent. * Capable of cooperating independently to complete the examinations. Exclusion Criteria: * Patients with other malignancies or severe comorbidities that affect their ability to participate. * Patients unable to provide informed consent due to cognitive impairment. * Patients with contraindications to PET/CT scans or 68Ga-PFA2 administration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer exocrine pancreatic carcinoma lung cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms、lung neoplasms、pancreatic neoplasms Exploring the diagnostic potential of 68GA-PFA2 pet imaging in annexin A2-positive tumors, including breast cancer, lung cancer, and pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking university first hospital nuclear medicine

    RECRUITING

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.